Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206891 | 0.86 | ARG1 (0.44) | SIGMAR1POLBS1PR2S1PR1S1PR3 | |
| SCHEMBL894670 | 0.72 | ARG1 (0.46) | SMN1; SMN2CHRM2KDM4ETHRBTDP1 | |
| Hydrochloric Acid SCHEMBL894540 | 0.72 | ARG1 (0.46) | SMN1; SMN2CHRM2KDM4ETHRBTDP1 | |
| SCHEMBL10206900 | 0.71 | ARG1 (0.48) | FOLH1SIGMAR1POLB | |
| SCHEMBL11672256 | 0.70 | CHRM2 (0.83) | SMN1; SMN2CHRM2KDM4ETHRBTDP1 | |
| SCHEMBL19434652 | 0.70 | CHRM2 (0.91) | SMN1; SMN2CHRM2KDM4ETHRBTDP1 | |
| SCHEMBL11094422 | 0.70 | CHRM2 (0.75) | SMN1; SMN2CHRM2KDM4ETHRBTDP1 | |
| SCHEMBL16249293 | 0.69 | DRD2 (0.51) | — | |
| SCHEMBL894883 | 0.68 | FOLH1 (0.49) | FOLH1LMNA | |
| Hydrochloric Acid SCHEMBL895695 | 0.68 | FOLH1 (0.48) | FOLH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161349-A1 | ARGINASE INHIBITOR COMBINATION THERAPIES | PRECISION PHARMACEUTICALS, INC. | 2018-06-14 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-20160375044-A1 | Compositions and Methods for Inhibiting Arginase Activity | CALITHERA BIOSCIENCES, INC. | 2016-12-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375044-A1 | Compositions and Methods for Inhibiting Arginase Activity | ARG1, ARG2, PRMT3 | SMN1; SMN2 4290/4885CHRM2 2761/4885KDM4E 1380/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885CHRM2 20/4885KDM4E 804/4885 |
| US-20180161349-A1 | ARGINASE INHIBITOR COMBINATION THERAPIES | ARG1, ARG2, PRMT3 | SMN1; SMN2 1823/4885CHRM2 758/4885KDM4E 2471/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885CHRM2 20/4885KDM4E 804/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885CHRM2 20/4885KDM4E 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.